Targeted chemotherapy or placebo to treat patient with lung cancer that has been completely removed by surgery

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
Data is not saved in preview.
"Can targeted chemotherapy (Erlotinib) stop the growth of tumor cells by blocking some of the enzymes needed for cell growth?"
Age:
18 to 100 years old
Gender:
Any
Healthy Volunteers:
No
Keywords:
lung cancer, cancer, chemotherapy, surgery
Type:
Drug study, Phase 3
Investigator:
Description
This study looks at how well targeted chemotherapy, erlotinib hydrochloride, compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
This study requires
Please contact for details
Who can participate?
Inclusion Criteria:

- Previously registered to A151216, with the result of lung cancer harboring an EGFR exon 19 deletion or L858R mutation; the testing must have been performed by one of the following criteria:

1. Patient registered to A151216 and the assessment performed centrally by the protocol specified laboratory

2. By a local Clinical Laboratory Improvement Amendments (CLIA) certified laboratory; the report must indicate the result as well as the CLIA number of the laboratory that performed the assay; these patients will also have been registered to A151216, but can be enrolled on A081105 regardless of the central lab results

- Patients with known resistant mutations in the EGFR tyrosine-kinase (TK) domain (T790M) are not eligible

- Patients that are both EGFR mutant and anaplastic lymphoma kinase (ALK) rearrangements will be registered to A081105

- Completely resected stage IB (>= 4 cm), II or IIIA non-squamous NSCLC with negative margins

- Complete recovery from surgery and standard post-operative therapy (if required); patients must be completely recovered from surgery at the time of randomization; the minimum time requirement between date of surgery and randomization must be at least 28 days, the maximum time requirement between surgery and randomization must be 90 days if no adjuvant chemotherapy was administered, 240 days if adjuvant chemotherapy was administered, and 300 days if adjuvant chemotherapy and radiation therapy was administered

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1

- No prior or concurrent malignancies within 5 years, except non-melanoma skin carcinoma and in situ carcinomas

- Non-pregnant and non-lactating

- No history of cornea abnormalities

- Granulocytes >= 1,500/ul

- Platelets >= 100,000/ul

- Total bilirubin =< 1.5 x upper limit of normal (ULN)

- Serum glutamic oxaloacetic transaminase (SGOT) =< 1.5 x ULN

- Serum creatinine =< 1.5 x ULN
Resources
Schedule
Study duration and period
Please contact for details
Recruitment period
From March 19, 2015
Location
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Research Topic
Conditions:
  • Stage IB Non-Small Cell Lung Carcinoma
  • Stage IIA Non-Small Cell Lung Carcinoma
  • Stage IIB Non-Small Cell Lung Carcinoma
  • Stage IIIA Non-Small Cell Lung Cancer

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Sending

Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:


E-mail Preview